ENANTA PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ENANTA PHARMACEUTICALS, INC (ENTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $31.84 per share for the 12-month period ending 2018-09-30, per its 10-K filed 2018-11-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2018-11-29
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $31.84, a 81.74% increase from fiscal 2017.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $17.52, a 8.37% decline from fiscal 2016.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $19.12, a 31.15% decline from fiscal 2015.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $27.77, a 38.99% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2018-09-30 | $31.84 10-K · filed 2018-11-29 |
| 2017-09-30 | $17.52 10-K · filed 2018-11-29 |
| 2016-09-30 | $19.12 10-K · filed 2018-11-29 |
| 2015-09-30 | $27.77 10-K · filed 2017-12-11 |
| 2014-09-30 | $19.98 10-K · filed 2016-12-09 |
| 2013-09-30 | $9.16 10-K · filed 2015-12-11 |
| 2012-09-30 | $7.79 10-K · filed 2014-12-11 |
| 2011-09-30 | $1.95 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |